Corbus Pharmaceuticals Holdings Inc(NASDAQ : CRBP)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -0.31% | 86.00 | 1.3% | $1325.78m | |
| AMGN | Amgen Inc. | -0.93% | 201.98 | 1.2% | $608.04m | |
| GILD | Gilead Sciences, Inc. | -0.91% | 68.55 | 0.9% | $534.22m | |
| LOXO | Loxo Oncology Inc | 0.12% | 233.78 | 12.7% | $511.41m | |
| BIIB | Biogen Inc. | 0.46% | 338.96 | 1.3% | $413.85m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.42% | 193.88 | 1.9% | $324.40m | |
| ILMN | Illumina, Inc. | -2.92% | 303.62 | 3.5% | $304.88m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -3.36% | 404.75 | 2.6% | $294.14m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -2.36% | 114.29 | 2.0% | $213.93m | |
| INCY | Incyte Corporation | -1.39% | 77.33 | 2.5% | $145.56m | |
| A | Agilent Technologies, Inc. | -0.89% | 71.29 | 1.5% | $145.13m | |
| EXAS | Exact Sciences Corporation | -3.46% | 76.07 | 25.3% | $135.78m | |
| SRPT | Sarepta Therapeutics, Inc. | -2.05% | 120.28 | 15.4% | $130.09m | |
| LGND | Ligand Pharmaceuticals Incorporated | -4.23% | 112.91 | 23.1% | $119.15m | |
| NBIX | Neurocrine Biosciences, Inc. | -0.27% | 91.28 | 5.1% | $97.05m |
Company Profile
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in December 2013 and is headquartered in Norwood, MA.